RxDoctor Payments Data

Jennifer Roberts

Psychiatric/Mental Health · Framingham, MANPI 1194418947

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 58 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395
  • E.r. Squibb & Sons, L.L.C.$339
  • AbbVie$261
  • Alkermes, Inc.$243
  • Lundbeck LLC$178
  • Otsuka America Pharmaceutical, Inc.$153
  • plus $524 from 4 others

What the payments were for

  • Food & beverage$2,092100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,093 in reported general payments places this provider in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$20,363
Medicare patients
20
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl21$29,383
CaplytaLumateperone Tosylate14$22,696
Fluvoxamine Maleate19$918
Bupropion XlBupropion Hcl34$818
Lamotrigine67$763
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$736
Methylphenidate Hcl21$648
Clonazepam83$577
Gabapentin31$482
Duloxetine Hcl11$400
Sertraline Hcl31$382
Lithium Carbonate12$342
Trazodone Hcl41$342
Mirtazapine17$297
Venlafaxine Hcl ErVenlafaxine Hcl34$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$261$29,38321 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$395$22,69614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →